AR064327A1 - Un metodo para preparar montelukast e intermediarios utilizados en el mismo - Google Patents

Un metodo para preparar montelukast e intermediarios utilizados en el mismo

Info

Publication number
AR064327A1
AR064327A1 ARP070105594A ARP070105594A AR064327A1 AR 064327 A1 AR064327 A1 AR 064327A1 AR P070105594 A ARP070105594 A AR P070105594A AR P070105594 A ARP070105594 A AR P070105594A AR 064327 A1 AR064327 A1 AR 064327A1
Authority
AR
Argentina
Prior art keywords
formula
compound
montelukast
same
ethyl
Prior art date
Application number
ARP070105594A
Other languages
English (en)
Inventor
Young-Kil Chang
Chul Hyun Park
Jaeho Yoo
Gwan Sun Lee
Jaeheon Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR064327A1 publication Critical patent/AR064327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Reivindicacion 1: Un método para reparar montelukast o su sal de sodio de la formula (1) que comprende las etapas de: (a) permitir que un compuesto halofosfato de la formula (5) reaccione con el compuesto diol de la formula (4) en un solvente en presencia de una base para producir un compuesto fosfato de la formula (3) y (b) acoplar el compuesto fosfato de la formula (3) con un compuesto ácido tiocarboxílico de la formula (2) en un solvente en presencia de una base: en donde, R es H o Na; R1 es H, metilo, o etilo; R2 es metilo, etilo, o fenilo; X es halogeno; Y es azufre u oxígeno. Reivindicacion 11: Un compuesto fosfato de la formula (3), el cual es utilizado como un intermediario para producir montelukast o su sal de sodio de acuerdo con la reivindicacion 1: en donde, R2 es metilo, etil, o fenilo; Y es azufre u oxígeno.
ARP070105594A 2006-12-14 2007-12-13 Un metodo para preparar montelukast e intermediarios utilizados en el mismo AR064327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060127942A KR100774088B1 (ko) 2006-12-14 2006-12-14 몬테루카스트의 제조방법 및 이에 사용되는 중간체

Publications (1)

Publication Number Publication Date
AR064327A1 true AR064327A1 (es) 2009-03-25

Family

ID=39061099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105594A AR064327A1 (es) 2006-12-14 2007-12-13 Un metodo para preparar montelukast e intermediarios utilizados en el mismo

Country Status (12)

Country Link
US (1) US8217174B2 (es)
EP (1) EP2114889B1 (es)
JP (1) JP5017696B2 (es)
KR (1) KR100774088B1 (es)
CN (1) CN101558042B (es)
AR (1) AR064327A1 (es)
CA (1) CA2673098C (es)
ES (1) ES2446016T3 (es)
MX (1) MX2009005164A (es)
RU (1) RU2408583C1 (es)
TW (1) TWI382017B (es)
WO (1) WO2008072872A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904448B1 (en) 2005-07-05 2011-02-02 Teva Pharmaceutical Industries, Ltd. Purification of montelukast
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
WO2009138993A1 (en) * 2008-05-13 2009-11-19 Macleods Pharmaceuticals Limited A process for preparation of montelukast sodium salt
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
KR100893756B1 (ko) * 2009-01-14 2009-04-22 주식회사 메디켐코리아 몬테루카스트의 효율적 제조방법
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
CN104293850B (zh) * 2014-08-12 2017-08-04 江苏恒盛药业有限公司 孟鲁司特钠的制备工艺及其中间产物
CN106831863B (zh) * 2017-01-20 2018-09-21 山东百诺医药股份有限公司 孟鲁司特钠中间体及其制备方法和应用
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
CN111892535B (zh) * 2020-08-27 2023-04-11 鲁南制药集团股份有限公司 一种孟鲁司特钠的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
WO1998039970A1 (en) * 1997-03-13 1998-09-17 Merck & Co., Inc. Quinoline leukotriene antagonists
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
WO2005105751A1 (en) 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
WO2006008751A2 (en) 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
WO2006058545A1 (en) 2004-11-30 2006-06-08 Medichem, S.A. New process for the preparation of a leukotriene antagonist

Also Published As

Publication number Publication date
RU2408583C1 (ru) 2011-01-10
JP5017696B2 (ja) 2012-09-05
CN101558042A (zh) 2009-10-14
CA2673098C (en) 2011-10-04
US8217174B2 (en) 2012-07-10
TW200831466A (en) 2008-08-01
CA2673098A1 (en) 2008-06-19
ES2446016T3 (es) 2014-03-06
US20100099876A1 (en) 2010-04-22
CN101558042B (zh) 2011-05-18
EP2114889A4 (en) 2010-12-22
JP2010512309A (ja) 2010-04-22
WO2008072872A1 (en) 2008-06-19
KR100774088B1 (ko) 2007-11-06
MX2009005164A (es) 2009-05-27
EP2114889A1 (en) 2009-11-11
TWI382017B (zh) 2013-01-11
EP2114889B1 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
AR064327A1 (es) Un metodo para preparar montelukast e intermediarios utilizados en el mismo
UY33357A (es) Uracilos herbicidas
CO6382079A2 (es) Composiciones insecticidas estables a base de sulfoximina
ECSP099529A (es) Inhibidores de cinasa mapk/erk
CO6280580A2 (es) Derivados herbicidas de piridazinona
ATE554065T1 (de) Sulfoniumsalz-fotoinitiatoren
CR10346A (es) Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3
UY31633A1 (es) Plaguicidas mesoiónicos
EA200702549A1 (ru) Способ производства органического соединения
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
BRPI0713357A2 (pt) Inibidores de proteína tirosina fosfatase humana e método de utilização.
BR0317696A (pt) Composição para branqueamento
AR062568A1 (es) Imprimante universal
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
GT200500311A (es) Compuestos organicos
CO5601045A2 (es) Procedimiento para la fabricacion de compuestos organicos
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
GT200600208A (es) Compuestos organicos
SV2009003253A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
HN2005000114A (es) Procedimiento para purificar mesotriona.
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SV2008002512A (es) Derivados de aminoacidos ref. pc32769a
ECSP088901A (es) Método para preparar intermediarios de quinolina 4-halogenados

Legal Events

Date Code Title Description
FB Suspension of granting procedure